Avantor, Inc. (AVTR) – What Are Researchers Saying About This Stock?

Avantor, Inc. (NYSE:AVTR) has earned a consensus rating of “Hold” from the eighteen brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, fifteen have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $13.24.

AVTR has been the subject of a number of research reports. Citigroup boosted their price target on Avantor from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Wolfe Research upgraded Avantor from a “strong sell” rating to a “hold” rating in a report on Thursday, July 30th. Barclays raised their price objective on Avantor from $13.00 to $15.00 and gave the stock an “underweight” rating in a report on Wednesday, October 7th. Jefferies Financial Group raised Avantor from an “underperform” rating to a “hold” rating and set a $13.00 target price for the company in a research report on Wednesday, July 29th. Finally, Wall Street Zen upgraded Avantor from a “hold” rating to a “buy” rating in a report on Sunday.

Avantor Trading Up 0.6%

AVTR stock opened at $15.59 on Wednesday. Avantor has a 12 month low of $7.26 and a 12 month high of $16.38. The firm’s 50-day moving average is $14.74 and its 200 day moving average is $11.25. The company has a market capitalization of $10.54 billion, a PE ratio of 18.89, a P/E/G ratio of 8.81 and a beta of 0.94. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.78 and a quick ratio of 1.18.

Avantor (NYSE:AVTR) last released its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.02. The company had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.61 billion. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The firm’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the previous year, the company earned $0.24 EPS. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, research analysts anticipate that Avantor will post 0.81 EPS for the current year.

Institutional Investors Weigh In On Avantor

Several hedge funds have recently modified their holdings of AVTR. BlackRock Inc. acquired a new position in Avantor during the 2nd quarter valued at approximately $695,784,000. Engine Capital Management LP increased its position in shares of Avantor by 65.8% in the 1st quarter. Engine Capital Management LP now owns 19,780,830 shares of the company’s stock valued at $155,082,000 after acquiring an additional 7,853,018 shares during the period. Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of Avantor in the 2nd quarter valued at $195,386,000. Dimensional Fund Advisors LP raised its stake in Avantor by 15.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 16,894,649 shares of the company’s stock worth $132,443,000 after acquiring an additional 2,288,053 shares during the last quarter. Finally, Clarkston Capital Partners LLC raised its stake in Avantor by 0.6% in the 4th quarter. Clarkston Capital Partners LLC now owns 15,105,065 shares of the company’s stock worth $173,104,000 after acquiring an additional 84,740 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Avantor

Avantor, Inc is a global provider of products, services and solutions used in the life sciences and advanced technology industries. The company supplies materials and equipment that support research, drug discovery and development, biopharmaceutical manufacturing, clinical and diagnostic activities, and other laboratory applications.

Its offerings include laboratory chemicals and reagents, consumables, single-use manufacturing technologies, bioprocessing products, equipment, and related services.